about
Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines - An Isobolographic Analysis.Tumor neovasculature-targeted cationic PEGylated liposomes of gambogic acid for the treatment of triple-negative breast cancerPotential options for managing LOX+ ER- breast cancer patientsWnt-beta-catenin pathway signals metastasis-associated tumor cell phenotypes in triple negative breast cancers.Identification of recurrent BRCA1 mutation and its clinical relevance in Chinese Triple-negative breast cancer cohort.DNA repair genes PAXIP1 and TP53BP1 expression is associated with breast cancer prognosis.Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers.Identification of deubiquitinase targets of isothiocyanates using SILAC-assisted quantitative mass spectrometry.Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes.PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.5,6,7,3',4',5'-Hexamethoxyflavone inhibits growth of triple-negative breast cancer cells via suppression of MAPK and Akt signaling pathways and arresting cell cycle.Worse survival after breast cancer in women with anorexia nervosa.MxA expression is associated with tumor-infiltrating lymphocytes and is a prognostic factor in triple-negative breast cancer.The Dietary Flavonoid Fisetin Causes Cell Cycle Arrest, Caspase-Dependent Apoptosis, and Enhanced Cytotoxicity of Chemotherapeutic Drugs in Triple-Negative Breast Cancer Cells.Friend leukemia virus integration 1 is a predictor of poor prognosis of breast cancer and promotes metastasis and cancer stem cell properties of breast cancer cellsImmunopeptidomic Profiling of HLA-A2-Positive Triple Negative Breast Cancer Identifies Potential Immunotherapy Target Antigens
P2860
Q35845089-81BE72EB-364F-4E0C-9008-39827503F66BQ37258973-2433E511-065A-4D8F-9A88-2B5DEB6F1454Q37362796-4C90B075-2FC4-4A96-8FD9-D4197C7AA97CQ37536500-C7BD4157-72A9-402E-855C-4EE572B6784AQ37693410-6747ACE7-ADA9-4F9B-864A-C6560F3F6B68Q38802323-40BCEEEC-A797-4EB6-A16A-5A828D939DA2Q41078110-70F3780D-4D18-43B8-A2A4-A88FFE01BC5BQ41612750-4808BE86-95E4-438F-A6D1-BDA7635B5B2FQ42275833-DC039AD4-AE77-4D03-8F0A-FDF379EABC8EQ42517340-FE09D8DB-9CF0-4B7E-B738-D023DC50114CQ47163874-B8BDAD37-E1B6-46CA-8359-B061A172CA3DQ47319668-D66F5C4C-3C8E-4FB9-9793-EE003D92D566Q53122691-C4DCC9E3-ABC6-49F0-B9EE-1C25719ACF2EQ55032232-D206B4CB-CC3D-4346-85BF-69166FE9E292Q57171708-FA43B33E-61E9-467A-B182-2225DE949BC9Q58214193-9FEC384D-CB10-40DD-B170-678CD5FFD674
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Therapies for triple negative breast cancer.
@en
type
label
Therapies for triple negative breast cancer.
@en
prefLabel
Therapies for triple negative breast cancer.
@en
P2093
P2860
P1476
Therapies for triple negative breast cancer.
@en
P2093
Eleni Andreopoulou
Hayley M McDaid
Joseph A Sparano
Sarah J Schweber
P2860
P304
P356
10.1517/14656566.2015.1032246
P407
P577
2015-05-01T00:00:00Z